Table 3 Hazard ratios of CVD events by multivariate Cox regression analyses using models including TG and/or HDL-C.

From: Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease

Model

Variable

HR

95% CI

P value

Model 4 + TG

TG/HDL-C index ≥ 2.5

(vs. TG/HDL-C index < 2.5)

1.68

1.24–2.28

0.001

TG (per 10 increase)

1.01

1.00–1.03

0.10

Model 4 + HDL-C

TG/HDL-C index ≥ 2.5

(vs. TG/HDL-C index < 2.5)

1.88

1.38–2.57

 < 0.001

HDL-C (per 1 increase)

1.00

0.99–1.01

0.94

Model 4 + TG, HDL-C

TG/HDL-C index ≥ 2.5

(vs. TG/HDL-C index < 2.5)

1.67

1.19–2.36

0.003

TG (per 10 increase)

1.01

1.00–1.03

0.10

HDL-C (per 1 increase)

1.00

0.99–1.01

0.96

Model 4 + non HDL-C

TG/HDL-C index ≥ 2.5

(vs. TG/HDL-C index < 2.5)

1.76

1.32–2.36

0.001

non HDL-C (per 1 increase)

1.00

1.00–1.01

0.30

Model 4 + Apo B

TG/HDL-C index ≥ 2.5

(vs. TG/HDL-C index < 2.5)

1.62

1.20–2.18

0.002

Apo B (per 1 increase)

1.01

1.00–1.03

0.020

  1. Multivariate Cox regression analyses were performed using models that included TG, HDL-C, non-HDL-C, or ApoB to assess whether the TG/HDL-C index was associated with CVD risk independently of these lipid parameters. Model 4 was adjusted for age, sex, statin treatment allocation of the EMPATHY study, body mass index, smoking, hypertension, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A1c, estimated glomerular filtration rate, log B-type natriuretic peptide, diabetic neuropathy or nephropathy, and prescribed drugs: Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor, calcium channel blocker, β-blocker, and diuretic. ApoB, apolipoprotein B; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.
Back to article page